The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients

European Journal of Pharmacology

Volumn 641, Issue 2-3, 2010, Pages 82-87

  Terrazzino, Salvatore ^a   Viana, Michele ^b   Floriddia, Elisa ^a   Monaco, Francesco ^b   Mittino, Daniela ^b   Sances, Grazia ^c   Tassorelli, Cristina ^c   Nappi, Giuseppe ^c   Rinaldi, Maurizio ^a   Canonico, Pier Luigi ^a,d   Genazzani, Armando A ^a,c,d  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d University Centre for Adaptive Disorders and Headache (UCADH) Section of Novara   (Italy)

Author keywords

Consistency; Headache response; Migraine; Serotonin transporter; STin2 polymorphism; Triptans

Indexed keywords

ALMOTRIPTAN; AMITRIPTYLINE; ELETRIPTAN; FLUNARIZINE; FROVATRIPTAN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT 3; PROTEIN STIN2; RIZATRIPTAN; SEROTONIN TRANSPORTER; SUMATRIPTAN; TAQ POLYMERASE; TOPIRAMATE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ADULT; ARTICLE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SOMNOLENCE; THORAX DISEASE; VARIABLE NUMBER OF TANDEM REPEAT; WEAKNESS;

ADULT; ALLELES; COHORT STUDIES; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; ITALY; LOGISTIC MODELS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MIGRAINE DISORDERS; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D2; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTAMINES;

EID: 77954085979     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.049     Document Type: Article

References (30)

1. Asuni C., Cherchi A., Congiu D., Piccardi M.P., Del Zompo M., Stochino M.E. Association study between clinical response to rizatriptan and some candidate genes. J. Headache Pain 2007, 8:185-189.
2. Buzzi M.G. Pathways to the best fit of triptans for migraine patients. Cephalalgia 2008, 28:21-27.
3. Diener H.C., Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin. Investig. Drugs 2001, 10:1831-1845.
4. Dodick D.W. Triptan nonresponder studies: implications for clinical practice. Headache 2005, 45:156-162.
5. Dowson A.J., Mathew N.T., Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int. J. Clin. Pract. 2006, 60:698-706.
6. Durham L.K., Webb S.M., Milos P.M., Clary C.M., Seymour A.B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004, 174:525-529.
7. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Meth. 2007, 39:175-191.
8. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
9. Fiskerstrand C.E., Lovejoy E.A., Quinn J.P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 1999, 458:171-174.
10. Grandy D.K., Zhang Y., Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum. Mol. Genet. 1993, 2:2197.
11. Hensher D.A., Johnson L.W. Applied Discrete-Choice Modelling 1981, Croom Helm, London.
12. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., Goldman D.l. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 2006, 78:815-826.
13. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Müller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
14. Lesch K.P., Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:1062-1073.
15. Lesch K.P., Mössner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?. Biol. Psychiatry 1998, 44:179-192.
16. Mehrotra S., Vanmolkot K.R., Frants R.R., van den Maagdenberg A.M., Ferrari M.D., MaassenVanDenBrink A. The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan. Headache 2007, 47:711-716.
17. Ogilvie A.D., Russell M.B., Dhall P., Battersby S., Ulrich V., Smith C.A., Goodwin G.M., Harmar A.J., Olesen J. Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia 1998, 18:23-26.
18. Pini L.A., Brovia D. Different characteristics of triptans. J. Headache Pain 2004, 5:S109-S111.
19. Sandrini G., Dahlöf C.G., Mathew N., Nappi G. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. Int. J. Clin. Pract. 2005, 59:1356-1365.
20. Sarosi A., Gonda X., Balogh G., Domotor E., Szekely A., Hejjas K., Sasvari-Szekely M., Faludi G. Association of the STin2 polymorphism of the serotonin transporter gene with a neurocognitive endophenotype in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1667-1672.
21. Schürks M., Kurth T., Stude P., Rimmbach C., de Jesus J., Jonjic M., Diener H.C., Rosskopf D. G protein beta3 polymorphism and triptan response in cluster headache. Clin. Pharmacol. Ther. 2007, 82:396-401.
22. Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Sharma A.M., Ritz E., Wichmann H.E., Jakobs K.H., Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat. Genet. 1998, 18:45-48.
23. Silberstein S.D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754-762.
24. Smits K.M., Smits L.J., Peeters F.P., Schouten J.S., Janssen R.G., Smeets H.J., van Os J., Prins M.H. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr. Genet. 2008, 18:184-190.
25. Tfelt-Hansen P., Block G., Dahlof C., Diener H.C., Ferrari M.D., Goadsby P.J., Guidetti V., Jones B., Lipton R.B., Massiou H., Meinert C., Sandrini G., Steiner T., Winter P.B. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000, 20:765-786.
26. Tfelt-Hansen P., De Vries P., Saxena P.R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000, 60:1259-1287.
27. Velati D., Viana M., Cresta S., Mantegazza P., Testa L., Bettucci D., Rinaldi M., Sances G., Tassorelli C., Nappi G., Canonico P.L., Martignoni E., Genazzani A.A. 5-hydroxytryptamine 1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur. J. Pharmacol. 2008, 580:43-47.
28. Wendland J.R., Martin B.J., Kruse M.R., Lesch K.P., Murphy D.L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol. Psychiatry 2006, 11:224-226.
29. Wieser T., Dresler K., Evers S., Gaul C., König D., Hölzl D., Berger K., Nyholt D., Deufel T. No influence of 5-HTTLPR gene polymorphism on migraine symptomatology. Comorbid Depress. Chronification 2009, 10.1111/j.1526-4610.2009.01428.x.
30. Zalsman G., Huang Y.Y., Oquendo M.A., Burke A.K., Hu X.Z., Brent D.A., Ellis S.P., Goldman D., Mann J.J. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am. J. Psychiatry 2006, 163:1588-1593.